Implications of the FDA Guidance for a Risk-Based Approach to Monitoring and EMA Reflection Paper Risk Based Quality Management in Clinical Trials December 2018

Dec 14, 2018
Order the recording of this seminar

Course Description

FDA and EMA have communicated their expectations for trial oversight/ monitoring, monitoring systems, and investigative site oversight. These are described in the FDA Guidance Oversight of Clinical Investigations: A Risk- Based Approach to Monitoring and the EMA Reflection Paper on risk-based quality management in clinical trials, both of which will be reviewed in this web seminar, as well as industry think tank contributions.

Video Preview


Learning Objectives

  • Discuss the FDA Guidance and EMA Reflection Paper for clinical trial risk management and monitoring
  • Evaluate industry think tank trends (TransCelerate, CTTI)
  • Review best practices for risk management for trial oversight and monitoring

Who Should Attend

  • Clinical Investigators and Staff
  • Clinical Research Associates
  • Study and Clinical Research Associate Managers
  • Sponsors/CROs Clinical Operations
  • Clinical Quality Compliance and Quality Assurance Professionals


Elizabeth Ronk Nelson, MPH

Click here for complete trainer biographies


Hold this course at your company! For more information, contact Naila Ganatra at +1 215.413.2471.